EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The role of ubiquitin pathway‐mediated regulation of immune checkpoints in cancer immunotherapy

Xiaoming Zhou, Chengxiao Fu, Xisha Chen iD

Cancer · 2023-06 · 129 (11) · 1649-1661

DOI: 10.1002/cncr.34729 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer, 2023-03. Verfasst von Xiaoming Zhou und 2 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Research Institute, the First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China. Hauptthemen laut MEDLINE: Ubiquitin, Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 137 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

With the continuous cognition of the relationship between tumor cells and tumor immune microenvironment, immunotherapy based on the immune checkpoint blockade has achieved great breakthroughs, led to improved clinical outcomes, and prolonged survival for cancer patients in recent years. Nevertheless, the de novo or acquired resistance to immunotherapy has greatly counteracted the efficacy, leading to a 20%–40% overall response rate. Thus, further in‐depth understanding of the regulation of the tumor microenvironment and antitumor immunity is urgently warranted. Ubiquitination‐mediated protein degradation plays vital roles in protein stabilization, activation, and dynamics as well as in cellular homeostasis modulation. The dysregulated ubiquitination and deubiquitination are closely related to the changes in physiological and pathological processes, which subsequently result in a variety of diseases including cancer. In this review, the authors first summarize the current knowledge about the involvement of the ubiquitin‐proteasome system in tumor development with the ubiquitin conjugation‐regulated stability of p53, phosphatase and tensin homolog, and Myc protein as examples, then dissect the potential implications of ubiquitination‐mediated immune checkpoints degradation in tumor microenvironment and immune responses, and finally discuss the effects of therapeutically targeting the ubiquitin‐proteasome pathway on immunotherapy, with the goal of providing deep insights into the exploitation of more precise and effective combinational therapy against cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

UbiquitinNeoplasmsHumansProteasome Endopeptidase ComplexImmunotherapyUbiquitinationTumor Microenvironment

Stichwörter der Autor:innen

deubiquitinationimmune checkpointimmunotherapytumor microenvironmentubiquitination

Substanzen

UbiquitinProteasome Endopeptidase Complex

Autor:innen und Institutionen

  • Cancer Research Institute, the First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
  • Department of Pharmacy, School of Medicine, Hunan Normal University, Changsha, Hunan, China.
  • Department of Pharmacy, the First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
  • Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.

ORCID-Profile: Xisha Chen

Zitieren

APA

Zhou, X., Fu, C., & Chen, X. (2023). The role of ubiquitin pathway‐mediated regulation of immune checkpoints in cancer immunotherapy. Cancer, 129(11), 1649-1661. https://doi.org/10.1002/cncr.34729

Vancouver

Zhou X, Fu C, Chen X. The role of ubiquitin pathway‐mediated regulation of immune checkpoints in cancer immunotherapy. Cancer. 2023;129(11):1649-1661. doi:10.1002/cncr.34729

BibTeX
@article{Zhou2023,
  author = {Zhou, Xiaoming and Fu, Chengxiao and Chen, Xisha},
  title = {The role of ubiquitin pathway‐mediated regulation of immune checkpoints in cancer immunotherapy},
  journal = {Cancer},
  year = {2023},
  volume = {129},
  number = {11},
  pages = {1649--1661},
  doi = {10.1002/cncr.34729}
}
Kostenlos starten →